Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Study Initiation Checklist – V 2.0

Posted on By

BA-BE Studies: SOP for Study Initiation Checklist – V 2.0

Standard Operating Procedure for Study Initiation Checklist in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/031/2025
Supersedes SOP/BA-BE/031/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for the creation and use of a Study Initiation Checklist that ensures all regulatory, administrative, logistical, and operational activities are completed prior to the initiation of a Bioavailability/Bioequivalence (BA/BE) clinical study.

2. Scope

This SOP applies to all BA/BE studies managed or sponsored by the organization and is to be followed by study teams, investigators, clinical operations, and regulatory personnel prior to first subject enrollment.

3. Responsibilities

  • Clinical Project Manager: Oversees completion and documentation of the checklist.
  • Site Coordinator/CRA: Verifies and updates site-specific readiness.
  • Regulatory Affairs: Confirms submission and approval statuses.
  • QA/Compliance Team: Ensures checklist documentation is auditable and complete.
See also  BA-BE Studies: SOP for Selecting Bioequivalence Study Design (Crossover, Parallel, etc.) - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that no BA/BE study begins without a fully completed and approved Study Initiation Checklist on file.

5. Procedure

5.1 Checklist Preparation

  1. Use the standardized template from Annexure-1: Study Initiation Checklist Template.
  2. Customize checklist fields for the specific protocol/study based on sponsor and regulatory requirements.

5.2 Key Elements of the Checklist

  1. The checklist must include verification of:
    • Final Protocol Approval
    • Ethics Committee Approval Letter
    • Informed Consent Forms (all versions and languages)
    • Signed Clinical Trial Agreement
    • Insurance Coverage Document
    • Site Staff Training Certificates (Protocol & GCP)
    • Reference Product Procurement Status
    • Randomization Schedule Availability
    • Clinical Trial Supplies (Kits, Labels, CRFs)
    • Drug Storage and Calibration Records
    • Readiness of Pharmacokinetic Sample Handling Area
    • Medical Emergency SOP and Equipment Availability
See also  BA-BE Studies: SOP for Review of Regulatory Guidelines before Study Start - V 2.0

5.3 Checklist Completion and Approval

  1. Each item in the checklist must be signed and dated by the responsible team member.
  2. CRA verifies checklist accuracy during Site Initiation Visit (SIV).
  3. Clinical Project Manager signs off and files the checklist in the TMF/eTMF using Annexure-2: Study Initiation Completion Log.

5.4 Filing and Archiving

  1. Completed checklist to be filed in both physical and electronic format.
  2. Checklist must be accessible for audits, inspections, and internal reviews.

6. Abbreviations

  • SIV: Site Initiation Visit
  • CRA: Clinical Research Associate
  • CRF: Case Report Form
  • GCP: Good Clinical Practice
  • TMF: Trial Master File

7. Documents

  1. Study Initiation Checklist Template – Annexure-1
  2. Study Initiation Completion Log – Annexure-2
See also  BA-BE Studies: SOP for Regulatory Submission Planning for BE Studies - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • CDSCO Guidelines on Clinical Trials

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Study Initiation Checklist Template

Checklist Item Completed By Date Remarks
Final Protocol Signed Rajesh Kumar 14/04/2025 V2.0
EC Approval Received Sunita Reddy 15/04/2025 Received on time

Annexure-2: Study Initiation Completion Log

Study Code Site Code Date of Completion Verified By Remarks
BE-038 Site-102 17/04/2025 CRA Ready for FPFV

Revision History:

Revision Date Revision No. Details Reason Approved By
14/01/2022 1.0 Initial SOP New implementation QA Head
17/04/2025 2.0 Added site readiness elements, annexures Operational update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Tablets: SOP for Risk-Based Monitoring of Manufacturing Processes – V 2.0
Next Post: API Manufacturing: SOP for Handling of Quarantined Materials – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version